Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1240

Anetumab

Home » Anetumab

Background of Anetumab

Mesothelin (MSLN) is a differentiative antigen that is highly expressed in several human tumors, including mesothelioma, ovarian, and pancreatic cancers. As MSLN is overexpressed only in tumor tissues and not in adjacent normal tissues in pancreatic cancer, and is closely associated with tumor progression and migration, it has been proven to be a promising cancer biomarker and an effective target for cancer-targeted therapy.Modification with an anti-MSLN antibody would improve the targeting efficiency of diagnostic imaging agents and the drug-delivery system towards the MSLN-overexpressing pancreatic tumors.

Specifications

Catalog Number:
KB-1240
Antibody Name:
Anetumab
Isotype:
Human IgG1,lambda
FC Muations:
Wild Type
Target:
MSLN
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA | FACS
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overex-pressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3862.
  2. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-1428.
  3. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer. 2008;61:235-243.
  4. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10(12 Pt 1):3937-3942.7.